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Objective: To investigate the relationship between the
tumour volume and metabolic rates of astrocytic tumours
using MR spectroscopy (MRS) during radiation therapy (RT).
Methods: 12 healthy male Sprague-Dawley® rats (Sprague–
Dawley Animal Company, Madison, WI) were used, and a
tumour model was created through injecting C6 tumour
cells into the right caudate nuclei of the rats. Tumours grew
for 18 days after the injection and before the imaging study
and radiation treatment. MRS was performed with two-
dimensional multivoxel point-resolved spectroscopy se-
quence using a GE Signa VH/i 3.0-T MR scanner (GE
Healthcare, Milwaukee, WI) equipped with rat-special coil.
RT was given on the 19th day with a dose of 4Gy in one
single fraction. The image examinations were performed
before RT, and on the 4th, 10th, 14th and 20th days after
treatment, respectively. GE FuncTool software package (GE
Healthcare) was used for post-processing of spectrum.
Results: Metabolic ratios of serial MRS decrease pro-
gressively with time after RT. Choline-containing compo-
nents (Cho)/creatine and creatine phosphate (Cr) ratios
immediately prior to RT differed significantly from those
on the 10th, 14th and 20th days after RT; both Cho/N-
acetyl aspartate (NAA) ratios and NAA/Cr ratios imme-
diately prior to RT differed significantly from those on the
14th and 20th days after RT. A positive correlation between
changes of tumour volume and changes of Cho/Cr, lipid
and lactate/Cr and glutamate plus glutamine/Cr ratio was
observed on the 4th day after RT.
Conclusion:MRS provides potential in monitoring tumour
response during RT, and the imaging biomarkers predict
the response of astrocytic tumours to treatment.
Advances in knowledge: MRS is combined with both
tumour size and Ki-67 labelling index to access tumour
response to radiation.
More than 180,000 brain tumours (malignant and benign)
are diagnosed each year in the USA. Of these, about 23,380
are primary brain tumours.1 Among the primary brain
tumours, approximately 50% are glioblastoma multiform
(GBM) and 50% are gliomas. Glioma has been thought of
as a disease involving multiple gene mutations.2 It has al-
ways been difﬁcult for neurologists to diagnose and treat
glioma, especially GBM.3
Although conventional MRI can be used to detect brain
lesions, its sensitivity and speciﬁcity for distinguishing
between benign and malignant lesions and differentiating
between tumours and non-neoplastic lesions are limited.
Similar MRI features may be present in several different
tumour types. It is very difﬁcult to differentiate high-grade
and low-grade brain tumours with conventional MRI.4
The lack of biological markers with prognostic signiﬁcance
impedes the development of new treatment strategies.
Although some biomarkers can be identiﬁed through
molecular analysis5 and DNA microarray,6 these proce-
dures normally require diagnostic biopsies that may not be
feasible owing to tumour location. With the advancement
of MR spectroscopy (MRS), biologically relevant in-
tracellular metabolites can be detected, grading of astro-
cytomas can be assessed and their biological behaviour and
prognosis can be evaluated.7
MRS is a unique method for performing analysis of the
metabolism of organs and cells. It allows measurements of
metabolites for speciﬁc atomic nuclei and their compo-
nents, including choline-containing components (Cho),
creatine and creatine phosphate (Cr), N-acetyl aspartate
(NAA), lipid and lactate (LL) levels and glutamate plus
glutamine (Glx). The most commonly studied metabolites
in the brain are NAA, Cho and Cr.8–12 NAA is a predictor
for neuronal and axonal integrity since decreased levels are
usually observed after brain injury. The second most
commonly observed MRS ﬁnding after brain tumours is in-
creased Cho levels via cell membrane disruption and altered
phospholipid metabolism,13 which are biomarkers for cell
membrane turnover.14 The Cho level may be used to predict the
malignancy of gliomas.15 The Cho level has been found to
correlate with the cellular density of tumours.16 The Cr peak is
an indicator of cell energy metabolism17 and can be used to
distinguish pure tumours from pure necrosis.18 It has been
found that Cho and LL levels normalized to Cr are a strong
predictor of survival,19 especially when diagnostic biopsies are
not feasible. Glx changes arise from both neuronal and glial cells
and reﬂect cytoplasmic concentrations.20 The ratio of Glx/Cr
was increased in 10 patients of brain tumour with oedema,
which is associated with injury to the myelin sheath.21 High Glx/
Cr in vivo MRS index is a good predictor of tumour grading.22
Signiﬁcant correlations have been reported with hippocampal
volumetric measures and Glx/Cr in patients with schizophrenia
but not in healthy controls,23 although the relationship between
volume and Glx/Cr has been explored in brain tumours. Thus,
MRS potentially shows promise in brain tumour management.
The Ki-67 labelling index (LI) is a promising proliferation
marker in histological examination. Barbarella et al24 ﬁrst
reported that the Ki-67 LI was correlated with Cho/Cr ratio. It is
an independent predictor of both tumour recurrence and overall
survival in meningioma.25 It can be used to predict clinical
outcome in acromegalic patients.26 The Ki-67 LI increased at
higher histological grades.27 It is a reliable tool to accurately
determine the growth fraction of neoplasms in humans and
animals.28 Therefore, it has been used to predict clinical
outcome.
In this study, we tested our hypothesis that biomarkers illumi-
nated by MRS during radiation therapy (RT), including NAA,
Cho, LL and Glx/Cr, can add signiﬁcant predictive power to
clinical response to RT. We present the prognostic information
on these biomarkers and demonstrate that these provide useful
prognosis. We investigated the relationship between tumour
volume and the metabolic ratios, including Cho/Cr, LL/Cr and
Glx/Cr as well as the relationship between Ki-67 LI and the
metabolic ratios of these.
METHODS AND MATERIALS
Animal model of C6 glioma
12 healthy male Sprague-Dawley® rats (Sprague–Dawley Ani-
mal Company, Madison, WI) weighing between 250 and 300 g
(median weight, 275 g) were used in this study after approval
by the Institutional Animal Care and Use Committee of Fudan
University, Shanghai, China. They were fed and housed in the
Huashan Hospital at the Fudan University under aseptic con-
ditions. The tumour model was created by injecting cultured
cells of C6 glioma cell line into the brain of the rats.
Cell culture
Astrocytic tumour C6 cells were provided by the Institute of
Biochemistry and Cell Biology at the Shanghai Institute for
Biological Sciences. C6 cells were cultured in McCoy’s medium
supplemented with 10% heat-inactivated foetal bovine serum,
100Uml21 penicillin and 100mgml21 streptomycin. They were
maintained as exponentially growing monolayers at 37 °C in
a humidiﬁed atmosphere consisting of 95% air and 5% CO2.
Intracranial injection of tumour cells
An hour before starting intracranial (IC) injection, C6 cells were
washed once with phosphate-buffered saline solution, harvested
by trypsinization, counted and resuspended in serum-free
McCoy’s medium to a ﬁnal concentration of 1.23 106 cells
per 10ml. For IC injection, rats were anaesthetized by an in-
traperitoneal (IP) injection of a mixture of ketamine/xylazine
(60/7.5mg kg21, respectively). A volume of 10ml of cell sus-
pension was slowly injected into the right caudate–putamen of
the animal’s brain, as described in the literature.29 Buprenor-
phine was injected subcutaneously right after the injection of tu-
mour cells for optimal pain management (0.05mg kg21; v5 1ml).
Animal handling during MR acquisition
Animals were anaesthetized using a mixture of isoﬂurane in O2
(3%, 1.5mlmin21). Then, they were placed on an electric
heating pad and maintained under anaesthesia using a nose cone
(1–2% isoﬂurane in O2, 1.5mlmin
21) throughout the imaging
session. A 24-G catheter was secured into the animal’s tail vein
to allow for intravenous injection of hyperpolarized (1-13C)
pyruvate. Rats were placed in a custom-made cradle for posi-
tioning the brain in the centre of the radiofrequency (RF) coil
and in the centre of a magnet. A water-heating pad was used to
maintain stable body temperature of the animals throughout the
imaging session.
Customized special coil for rats was conﬁgured by using a
polyvinyl chloride pipe that is 15 cm in length and 6.4 cm in
inner diameter, which was wound around eight units of birdcage
coil. The solenoid coil had a diameter of 6.4 cm and a length of
10 cm and was placed in the RF shielding cylinder of 12 cm
outside diameter. Since the coil requires much lower energy than
the conventional 3-T MR head coil, we reduced transmit signals
by 20 db through an attenuator. Therefore, automatic scanning
software can be used to correct the energy transmitted to the RF
receiver as well as the gain received by the RF receiver.
Rat irradiation
The tumour model was created successfully in 18 days after
the implantation. The 12 rats were then treated with primary
RT, which included external beam RT with 6-MV photons (a
total of 4 Gy in one single fraction delivered to the head re-
gion of 23 2 cm between the anterior-bottom edges of both
eyes and anterior-bottom edges of both ears) using a clinical
linear accelerator (CLINAC-600C; Varian Medical Systems,
Palo Alto, CA). The machine used in our study was equipped
with a collimator of 120 leaves, which can create a maximal
ﬁeld size of 403 40 cm with 0.5-cm leaves in the central
203 20-cm region and 1-cm leaves in the outer 20-cm ﬁeld.
Irradiation to the rats was performed with the central ﬁeld
within 203 20 cm region. And to minimize the impact of leaf
width, we designed the two-dimensional (2D) treatment
plans through rotating the collimator such that the ends of
the leaves (rather than the sides of leaves) were used to conform
the treatment ﬁelds to the tumour. Figure 1 shows the isodose
distributions of a treatment plan for a rat brain tumour.
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MRI protocol, MR spectroscopy and tumour
volume measurement
Conventional MRI
All rats were examined using the 3.0-T MRI/MRS scanner (GE
Healthcare, Milwaukee, WI). Conventional MR sequences
were as follows: sagittal fast spin-echo T1 weighted imaging
for location; axial spin echo T1 weighted imaging [repeti-
tion time (TR)/echo time (TE)5 400/11ms; ﬁeld of view
(FOV)5 60mm; matrix5 2563 256; number of excitation
pulses5 2; bandwidth5 12.5 kHz; slice thickness5 1mm; in-
terslice gap5 0.2mm; total number of scan slices5 16]; fast
spin echo T2 weighted imaging (TR/TE5 4000/120ms; other
parameters identical to those used in the T1 weighted spin
echo sequence); and fast ﬂuid attenuation inversion recovery
(TR/TE5 4000/120ms; time of inversion5 2200ms; matrix5
2563 192; number of excitation pulses5one; other parameters
identical to those used in the T1 weighted spin-echo sequence).
MR spectroscopy
For all rats, an automated multivoxel 2D chemical shift imaging
sequence (TR5 1000ms; TE5 35ms; phase encoding x5 24;
phase encoding y5 24; number of excitation pulses5 one) was
used for 1H-MRS, and contralateral normal brain tissue was used
as a control. FOV was 60mm in diameter, slice thickness was
4mm and the voxel size of the MRS was 1.873 1.873 4mm3.
Tumour and 1H-MRS were located by T2 weighted imaging, and
shimming was performed by the MRI scanner automatically. The
volume of interest was chosen within the solid tumour so as to
avoid the strong interference from subcutaneous fat, haemor-
rhage, necrosis and the cystic part of the tumour. The total
duration for 2D 1H-MR spectrum acquisition was 580 s.
The noise level was estimated by computing the root-mean-
square (RMS) noise values over two 2.35-ppm wide regions of the
spectrum [the range of frequencies (24.51 ppm, 22.16 ppm)
and (2.86 ppm, 5.21 ppm)] and taking the greater of the two
levels. If the quantitative analysis routine ﬁnds and ﬁts a peak in
a region, a failure is reported if the signal-to-noise ratio (SNR)
of the peak is ,5 to 1, and/or the goodness of ﬁt of the peak
is ,4. The SNR is the usual signal-to-noise ratio; the noise is
estimated by taking the average RMS value over two regions of
data. The goodness of ﬁt is a ratio of the power of the peak (over
the ﬁtting region) vs the power of the residue. The power of the
peak is taken to be the lesser of the power of the data over the
region, and the power of the curve ﬁt data over the region. If
neither criterion is met, a failure is reported and “-ND-” (for not
detected) is displayed for the peak values.
Table 1. Change in both tumour volume and metabolic ratio on the fourth day after radiation therapy (RT)
Rat
Volume
(%)
Cho/
Cr (%)
Cho/
NAA
(%)
NAA/
Cr (%)
Lip0.9/
Cr (%)
Lipid and
lactate/Cr (%)
mI/Cr
(%)
Glutamate plus
glutamine/Cr (%)
1 1135 17 113 25 1108 152 123 170
2 294 231 27 226 143 227 19 247
3 295 222 22 221 117 117 133 140
4 299 210 27 24 143 230 141 217
5 294 211 116 224 121 254 219 117
6 1220 157 136 224 179 1118 237 175
7 262 230 223 29 1127 24 265 116
8 210 131 149 212 132 223 145 214
9 298 249 240 214 253 284 28 256
10 288 245 221 230 230 284 245 244
11 273 241 156 262 264 268 21 225
12 185 110 19 11 134 1273 1109 150
Cho, choline-containing components; Cr, creatine and creatine phosphate; Lip0.9, lipid signal at 0.9ppm; mI, myo-inositol; NAA, N-acetyl aspartate.
Figure 1. Isodose distributions of a treatment plan for a rat brain
using the central part of leaves with width of 0.5cm. Tumour
was contoured in yellow. The prescription lines are 100% (4Gy)
in red, 80% in green, 50% in light blue and 30% in blue. For colour
images see online: www.birpublications.org/doi/abs/10.1259.
bjr.20140418.
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MRS was acquired prior to RT and on the 4th, 10th, 14th and
20th day after the treatment. GE FuncTool 2.6.4b software (GE
Healthcare) was used to process the raw data that were stored in
a workstation.
Tumour volume measurement
On the 18th day after C6 glioma cell injection, conventional MRI
and MRS were used to observe the tumour volume and metabolic
information. Volumetric measurement was implemented by
manually contouring the tumour border on every slice using GE
FuncTool software. The percentage change of tumour volume is
deﬁned as (Vb2Va)/Va3 100%, where Va and Vb are tumour
volumes measured before and after RT, respectively.
Ki-67 labelling index
For pathology and Ki-67 immunohistochemical staining, the intact
skulls were removed and ﬁxed in 10% paraformaldehyde solution.
All procedures were performed under IP anaesthesia. Ki-67 LI is the
Figure 2. Change in tumour volume as well as the corresponding metabolites before radiation therapy (RT) and on the 4th, 10th, 14th
and 20th days after RT initiation.
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percentage of Ki-67-positive nuclei in the total number of tumour
cell nuclei per reference area. The tissue sample nearest to the
spectroscopic voxel was visually identiﬁed through comparison with
MR images and selected for the Ki-67 staining. The technique used
for Ki-67 staining of parafﬁn-embedded sections was described by
Shi et al.30 The sections were deparafﬁnized, placed in 300ml of
citrate buffer with a pH of 6.0 and heated ﬁve times for 3min each
at full power in a 500-W microwave oven so as to activate the
epitope of Ki-67 protein. After heating, the sections were reacted
with mindbomb homologue 1 (MIB-1) diluted 1:50 in phosphate-
buffered saline containing 1% normal rabbit serum and counter-
stained with methyl green. .1000 cells were counted in several
areas representative of the pathological characteristics, and the Ki-
67 LI was calculated as the percentage of positively stained nuclei.
Biostatistical methods
Quantitative data analysis was performed using SPSS® v. 19
(SPSS Inc., Chicago, IL). All of the data are presented as
means6 standard deviation (SD). The parameters in the two
groups before and after RT were compared using repeated
measures analysis of variance test, with p, 0.05 considered to be
statistical signiﬁcant. Pearson’s correlation was used to indicate
the relationship between two variables.
Receiver operating characteristics (ROC) analysis was used to
determine a cut-off value for Cho/Cr and its power of outcome
prediction was evaluated with Kaplan–Meier log-rank test.
RESULTS
In the 12 rats, it was found that the glioma cells were successfully
growing into tumours in these healthy rats, which showed in
conventional MRI and MRS images on the 18th day after cell
injection. The tumour volume was evaluated by T2 weighted
MRI and the average tumour volume was 272mm3 for these 12
rats. Of the 12, 9 volumes reduced on Day 4 after RT, as shown
in Table 1. Figure 2 shows the tumour volume change before and
Table 2. Metabolic ratios estimated by MR spectroscopy before and after radiation therapy (RT)
Time relative
to RT
initiation
Cho/Cr,
mean6
SD
Cho/
NAA,
mean6
SD
NAA/Cr,
mean6
SD
Lip0.9/
Cr,
mean6
SD
Lipid and
lactate/Cr,
mean6 SD
mI/Cr,
mean6
SD
Glutamate plus
glutamine/Cr,
mean6 SD
Prior to RT 1.716 0.32 1.206 0.24 1.496 0.40 0.606 0.27 2.186 1.91 1.446 0.44 0.926 0.35
4 days 1.496 0.55 1.246 0.29 1.176 0.33 0.766 0.51 1.716 1.67 1.396 0.42 0.906 0.45
10 days 1.156 0.39a 0.996 0.22 1.166 0.20 0.436 0.35 0.706 0.57 1.126 0.38 0.716 0.15
14 days 0.926 0.17a 0.866 0.14a 1.096 0.24 0.356 0.15 0.536 0.32 1.136 0.28 0.636 0.12
20 days 0.806 0.17a 0.776 0.23a 1.066 0.16a 0.316 0.14 0.526 0.24 0.996 0.16 0.606 0.12
Cho, choline-containing components; Cr, creatine and creatine phosphate; Lip0.9, lipid signal at 0.9ppm; mI, myo-inositol; NAA, N-acetyl aspartate;
SD, standard deviation.
aSignificant difference (p,0.01).
Figure 3. The change in metabolic ratios before and after radiation therapy (RT). Cho, choline-containing components; Cr, creatine
and creatine phosphate; Glx, glutamate plus glutamine; LL, lipid and lactate; NAA, N-acetyl aspartate.
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after RT. However, in the early phase of RT, three volumes
corresponding to rat 1, 6, 12, respectively, were observed
to increase at the fourth day after RT and decrease afterwards.
The metabolic ratios evaluated by serial MRS after RT de-
creased progressively as a function of time after RT, as shown in
Table 2. The metabolic ratios changed signiﬁcantly sometime
after RT as compared with those prior to RT, as shown in
Figure 3.
The metabolic ratios for three rats were found to increase
and then decrease. The change in the metabolic ratios
remains consistent with the change in the tumour volume.
Because there were tumour volume increases in three rats at
the early phase of RT, it is necessary to record the metabolic
changes. Table 1 summarizes the change in tumour volume
and metabolic ratios including Cho/Cr, Cho/NAA, NAA/Cr,
Lip/Cr, LL/Cr, myo-inositol (mI)/Cr and Glx/Cr for 12 rats at
fourth day after RT. Pearson correlations showed a signiﬁcant
correlation between tumour volume and the metabolic ra-
tios. For instance, tumour volume signiﬁcantly correlated with
Cho/Cr (r5 0.814; p5 0.001), LL/Cr (r5 0.72; p5 0.008) and
Glx/Cr (r5 0.775; p5 0.003), respectively. Figure 4 plots the
relative volume vs Cho/Cr, LL/Cr and Glx/Cr, respectively,
showing that a linear relationship exists.
Cho/Cr, LL/Cr and Glx/Cr are independent variables for iden-
tifying the change of tumour volumes. At Day 4 after RT, the
ROC analysis for the changes in Cho/Cr, LL/Cr and Glx/Cr
showed that the areas under the curve were 0.926, 1.000 and
1.000, respectively, and the optimal values were 21.5%, 6.5%
and 45.0%, respectively. These optimal values are able to identify
whether tumour volumes increase. For instance, the optimal
value of 45% in Glx/Cr can be used to separate tumour volumes
into two groups with the tumour volume increasing in one
group corresponding to the change of Glx/Cr .45% and the
tumour volume decreasing in the other group. These three
parameters were signiﬁcantly correlated with tumour volumes
(p5 0.033, 0.013 and 0.013, respectively) as shown in Table 3. A
new variable was created that was the multiplication of three
parameters (5Cho/Cr3LL/Cr3Glx/Cr) and was correlated with
tumour volumes. When these three parameters were combined,
the predictive power of tumour volume change was strength-
ened (p5 0.012) because of synergistic effect.
It has been found that there is a linear relationship between
Ki-67 LI and the Cho/Cr ratio through Pearson correlations
(r5 0.85; p, 0.0001), as shown in Figure 5a. Ki-67 LI has an
average of 0.353, ranging from 0.038 to 0.749. Ki-67 LI decreases
after RT as shown in Figure 6e,f and Figure 5b,c.
In a separate study with 62 rats of which 32 rats were injected
with the same C6 tumour cells and 30 rats were used as a control
group, our result of ROC analysis on Cho/Cr suggests that
tumours might have a higher grade as Cho/Cr .2.0. Kaplan–
Meier survival curves were obtained using the optimal value,
as shown in Figure 7.
DISCUSSION
This animal model with C6 gliomas generated in rats provides
great potential in studying tumour metabolites with MRS during
RT. This study investigated the utility of MRS in the identiﬁ-
cation of brain astrocytic tumour biomarkers, providing useful
information on using MRS biomarkers, such as NAA, Cho and
LL for evaluating brain astrocytic tumours. NAA is recognized
as an internal neural marker. It has a high peak in MRS of
normal brains and tends to decrease in increasing malignant
glioma.31 In this study, it is interesting to observe that NAA
decreases for 11 rats with increasing or decreasing volumes
Figure 4. The relative tumour volume vs (a) Cho/Cr, (b) LL/Cr
and (c) Glx/Cr, respectively. Cho, choline-containing components;
Cr, creatine and creatine phosphate; Glx, glutamate plus gluta-
mine; LL, lipid and lactate.
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during RT. NAA decrease might reﬂect the fact that the neu-
rons had been replaced by neoplasm, resulting in a decrease in
the number of neurons and thereby a decline in the signal.
However, for Rat 12, NAA/Cr increases as the tumour volume
increases. This might be associated with oedema and thereby
increasing neurons. In contrast to NAA, in astrocytomas, some
investigators reported that Cho signal intensities always in-
crease at a higher rate during more rapid development of
neoplasm.2 Other investigators pointed out that Cho peak
actually has three components that cannot be resolved with
magnetic ﬁelds ,3 T.13 Our results obtained by using a 3-T
MRI scanner show that Cho levels increase with increasing
tumour volume, in large parts owing to the increasing pro-
liferation rate and denser cellular density. Cho/Cr decreases as
tumour volumes decrease during RT. This might be explained
by the fact that the metabolic rate decreases and therefore
proliferation rate reduces during RT, which shows that Cho/Cr
can be used to indicate tumour response to RT.
In astrocytomas, the relationship between the tumour grade and
Cho levels exists with high-grade tumours having higher Cho
levels. This can be explained by higher membrane turnover in
aggressive tumours. However, it has been found that high-grade
tumours have lower Cho levels than do grade I or grade II
astrocytoma.32 This is due to the presence of necrosis in high-
grade tumours, which is associated with lower metabolites.33
High Cho levels are typically observed in non-necrotic high-
grade brain tumours, for example, anaplastic astrocytoma.4
Figure 5. Correlation of choline-containing components (Cho)/creatine and creatine phosphate (Cr) and Ki-67 labelling index (a)
and change of Ki-67 labelling index haematoxylin and eosin stain after radiation therapy (RT) (b) and after RT (c).
Table 3. Area under the curve (AUC) through receiver operating characteristics analysis on the fourth day after radiation therapy
Variable Cho/Cr
Cho/
NAA
NAA/
Cr
Lip0.9/
Cr
Lipid and lactate/
Cr
mI/Cr
Glutamate plus
glutamine/Cr
AUC 0.926 0.704 0.759 0.815 1.000 0.630 1.000
p-value 0.033 0.309 0.196 0.116 0.013 0.518 0.013
95% CI 0.77–1.00 0.41–0.99 0.43–1.00 0.56–1.00 1.00–1.00 0.22–1.00 1.00–1.00
Cho, choline-containing components; CI, confidence interval; Cr, creatine and creatine phosphate; Lip0.9, lipid signal at 0.9ppm; mI, myo-inositol;
NAA, N-acetyl aspartate.
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12 rats injected with C6 tumour cells grew into different grades
that were correlated with Cho levels. ROC analysis on Cho levels
provides an optimal value for classiﬁcation of grades because of
the signiﬁcant correlation between Cho and tumour grades.31,34
As shown in Figure 7, it turns out that the lifetime of a rat group
with Cho/Cr #2 is longer than that with Cho/Cr .2, indicating
the signiﬁcant correlation (p5 0.015) between survival and Cho
levels in the association with the tumour grade.
Lipid (at 1.3 ppm) and/or lactate (LL) peaks consist primarily of
lactate and secondarily of lipid because our methodology focused
on sensitization of lactate over lipid. Low LL signal is associated
with low-grade gliomas that are generally characterized by a rela-
tively high concentration of NAA, low Cho level and the absence of
LL.34 LL signal seems higher in grade IV and remains low in grade
II or III gliomas34,35 and the presence of lipid signal indicates the
necrosis and lipid storage inside the gliomas.36 Increased LL signal
predicts high-grade brain tumours, which generally contain a high
degree of necrosis.13 Visible lipids in MRS correlate with necrosis,
which cannot be differentiated from late-stage apoptosis through
standard histology. Therefore, such a correlation by MRS provides
useful prognostic information on the tumour grade.
The Glx peaks are deﬁned between 2.15 and 2.45 ppm. Glx
changes arise from both neuronal and glial cells and reﬂect cy-
toplasmic concentrations,20 thus Glx can be used as an in-
tercellular neurotransmitter marker. In our study, we observed
that the tumour volume increased when Glx/Cr was .45% and
decreased when Glx/Cr was ,45%. This gives us evidence that
Glx/Cr may be considered as a possible predictor of malignity
degree of brain tumours.
Brain tumours are usually heterogeneous with necrotic cores,
proliferative rims and invasion of surrounding tissues. The spec-
trum of MRS may vary from one region to another. Because of
lesion variability, tumour heterogeneity, dependence on data
Figure 6. Spectrum changes on the fourth day after radiation therapy (RT) with lactate increasing dramatically as tumour volume
increases. (a) MRI before RT; (b) MR spectroscopy (MRS) before RT; (c) MRI after RT; (d) MRS after RT; Ki-67 labelling index (e)
haematoxylin and eosin stain afer RT and (f) after RT.
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acquisition and analysis techniques, it is very difﬁcult to use MRS
alone to precisely diagnose a brain lesion. In this case, MRI should
be combined together with MRS. It is important to locate a region
of interest for sophisticated analysis. Heterogeneous spectroscopic
voxels through MR images normally indicate high Ki-67 LI,
whereas homogeneous spectroscopic voxels present low Ki-67 LI.15
After RT, Ki-67 LI decreases, as shown in Figure 5b,c. This might
be explained by the fact that tumour perfusion status improves
through RT and tumour volume decreases,37 and hence the status
of tumour heterogeneity changes.
MRS ﬁndings should be interpreted with caution because they
vary greatly with the time from brain injury to scan and also
vary with the patient’s age.14 For example, NAA levels in the
normal brain increase rapidly during maturation, reach a maxi-
mum around 10–15 years of age, and then decline slowly owing
to the decreased number of neurons.14 Although NAA/Cr ratios
have remained similar across studies, results should be inter-
preted cautiously because differences in the underlying patho-
physiological mechanisms were observed in experimental data
with the same NAA/Cr ratios. Our experimental design over-
comes the time variation in MRS studies because of the same
time scheme was used for the 12 rats at the same age.
In this study, the tumour volume varied from one rat to another.
The partial volume averaging may affect the accurate de-
termination in the tumour volume. As the tumour volume was
becoming small, the partial volume artefact would make it dif-
ﬁcult to delineate the tumour border. The main strategy for
decreasing partial volume artefacts is to use smaller, more
sharply deﬁned voxels. This means thinner sections, smaller
FOV and/or higher imaging matrix.
MRS is a very useful technique that allows the investigation of
biochemical pathology within the brain, including brain
tumours during RT, and provides reproducible diagnostic and
prognostic biomarkers for evaluating tumour biology and me-
tabolism. Our results suggest that the normalized Cho and
lactate correlate strongly with tumour volume change after RT,
which is an important prognostic factor for clinical outcome.
REFERENCES
1. Cancer facts and ﬁgure 2014. American
Cancer Society, Atlanta, GA; 2014. Available
from: www.cancer.org
2. Chen J, Huang SL, Li T, Chen XL. In vivo
research in astrocytoma cell proliferation
with 1H-magnetic resonance spectroscopy:
correlation with histopathology and immu-
nohistochemistry. Neuroradiology 2006; 48:
312–18.
3. Nano R, Lascialfari A, Corti M, Paolini A,
Pasi F, Corbella F, et al. New frontiers for
astrocytic tumours. Anticancer Res 2012; 32:
2755–8.
4. Horska´ A, Barker PB. Imaging of brain
tumors: MR spectroscopy and metabolic
imaging. Neuroimaging Clin N Am 2010; 20:
293–310. doi: 10.1016/j.nic.2010.04.003
5. Triscott J, Lee C, Foster C, Manoranjan B,
Pambid MR, Berns R, et al. Personalizing the
treatment of pediatric medulloblastoma:
polo-like kinase 1 as a molecular target in
high-risk children. Cancer Res 2013; 73:
6734–44. doi: 10.1158/0008-5472.CAN-12-
4331
6. Nutt CL, Mani DR, Betensky RA, Tamayo P,
Cairncross JG, Ladd C, et al. Gene
expression-based classiﬁcation of malignant
gliomas correlates better with survival than
histological classiﬁcation. Cancer Res 2003;
63: 1602–7.
7. Magalhaes A, Godfrey W, Shen Y, Hu J, Smith
W. Proton magnetic resonance spectroscopy
of brain tumors correlated with pathology.
Acad Radiol 2005; 12: 51–7.
8. Signoretti S, Marmarou A, Fatouros P, Hoyle
R, Beaumont A, Sawauchi S, et al. Applica-
tion of chemical shift imaging for measure-
ment of NAA in head injured patients. Acta
Neurochir Suppl 2002; 81: 373–5.
9. Holshouser BA, Tong KA, Ashwal S. Proton
MR spectroscopic imaging depicts diffuse
axonal injury in children with traumatic
brain injury. AJNR Am J Neuroradiol 2005;
26: 1276–85.
10. Holshouser BA, Tong KA, Ashwal S, Oyoyo
U, Ghamsary M, Saunders D, et al. Pro-
spective longitudinal proton magnetic reso-
nance spectroscopic imaging in adult
traumatic brain injury. J Magn Reson Imaging
2006; 24: 33–40.
11. Belanger HG, Vanderploeg RD, Curtiss G,
Warden DL. Recent neuroimaging techniques
in mild traumatic brain injury. J Neuropsy-
chiatry Clin Neurosci 2007; 19: 5–20.
12. Govind V, Gold S, Kaliannan K, Saigal G,
Falcone S, Arheart KL, et al. Whole-brain
proton MR spectroscopic imaging of mild-
to-moderate traumatic brain injury and
correlation with neuropsychological deﬁcits.
J Neurotrauma 2010; 27: 483–96. doi:
10.1089/neu.2009.1159
13. Astrakas LG, Zurakowski D, Tzika AA,
Zariﬁ MK, Anthony DC, De Girolami U,
et al. Noninvasive magnetic resonance
spectroscopic imaging biomarkers to
predict the clinical grade of pediatric
Figure 7. Kaplan–Meier survival analysis for choline-containing
components (Cho)/creatine and creatine phosphate (Cr)
(p50.015).
Full paper: MRS in rat with C6 glioma during RT BJR
9 of 10 birpublications.org/bjr Br J Radiol;88:20140418
brain tumors. Clin Cancer Res 2004; 10:
8220–8.
14. Shekdar K, Wang DJ. Role of magnetic
resonance spectroscopy in evaluation of
congenital/developmental brain abnormali-
ties. Semin Ultrasound CT MR 2011; 32:
510–38. doi: 10.1053/j.sult.2011.08.001
15. Shimizu H, Kumabe T, Shirane R, Yoshimoto
T. Correlation between choline level mea-
sured by proton MR spectroscopy and Ki-67
labeling index in gliomas. AJNR Am J
Neuroradiol 2000; 21: 659–65.
16. Croteau D, Scarpace L, Hearshen D, Gutierrez J,
Fisher JL, Rock JP, et al. Correlation between
magnetic resonance spectroscopy imaging
and image-guided biopsies: semiquantitative
and qualitative histopathological analyses of
patients with untreated glioma. Neurosurgery
2001; 49: 823–9.
17. Signoretti S, Di Pietro V, Vagnozzi R,
Lazzarino G, Amorini AM, Belli A, et al.
Transient alterations of creatine, creatine
phosphate, N-acetylaspartate and high-
energy phosphates after mild traumatic brain
injury in the rat. Mol Cell Biochem 2010; 333:
269–77. doi: 10.1007/s11010-009-0228-9
18. Rock JP, Hearshen D, Scarpace L, Croteau D,
Gutierrez J, Fisher JL, et al. Correlations
between magnetic resonance spectroscopy
and image-guided histopathology, with spe-
cial attention to radiation necrosis. Neuro-
surgery 2002; 51: 912–19; discussion 19–20.
19. Marcus KJ, Astrakas LG, Zurakowski D,
Zariﬁ MK, Mintzopoulos D, Poussaint TY,
et al. Predicting survival of children with
CNS tumors using proton magnetic reso-
nance spectroscopic imaging biomarkers. Int
J Oncol 2007; 30: 651–7.
20. Maddock RJ, Buonocore MH. MR spectro-
scopic studies of the brain in psychiatric
disorders. Curr Top Behav Neurosci 2012; 11:
199–251.
21. Ricci R, Bacci A, Tugnoli V, Battaglia S, Maffei
M, Agati R, et al. Metabolic ﬁndings on 3T 1H-
MR spectroscopy in peritumoral brain edema.
AJNR Am J Neuroradiol 2007; 28: 1287–91.
22. Calvar JA, Meli FJ, Romero C, Calcagno ML,
Ya´nez P, Martinez AR, et al. Characterization
of brain tumors by MRS, DWI and Ki-67
labeling index. J Neurooncol 2005; 72: 273–80.
23. Kraguljac NV, White DM, Reid MA, Lahti
AC. Increased hippocampal glutamate and
volumetric deﬁcits in unmedicated patients
with schizophrenia. JAMA Psychiatry 2013;
70: 1294–302. doi: 10.1001/
jamapsychiatry.2013.2437
24. Barbarella G, Ricci R, Pirini G, Tugnoli V,
Tosi MR, Bertoluzza A, et al. In vivo single
voxel 1H MRS of glial brain tumors:
correlation with tissue histology and in vitro
MRS. Int J Oncol 1998; 12: 461–8.
25. Bruna J, Brell M, Ferrer I, Gimenez-Bonafe P,
Tortosa A. Ki-67 proliferative index predicts
clinical outcome in patients with atypical or
anaplastic meningioma. Neuropathology
2007; 27: 114–20.
26. Fusco A, Zatelli MC, Bianchi A, Cimino V,
Tilaro L, Veltri F, et al. Prognostic signiﬁ-
cance of the Ki-67 labeling index in growth
hormone-secreting pituitary adenomas. J
Clin Endocrinol Metab 2008; 93: 2746–50.
doi: 10.1210/jc.2008-0126
27. Turkoglu E, Kertmen H, Sanli AM, Onder E,
Gunaydin A, Gurses L, et al. Clinical outcome
of adult choroid plexus tumors: retrospective
analysis of a single institute. Acta Neurochir
(Wien) 2014; 156: 1461–8. doi: 10.1007/
s00701-014-2138-1
28. Pereira RS, Schweigert A, Dias de Melo G,
Fernandes FV, Sueiro FA, Machado GF. Ki-67
labeling in canine perianal glands neoplasms:
a novel approach for immunohistological
diagnostic and prognostic. BMC Vet Res
2013; 9: 83. doi: 10.1186/1746-6148-9-83
29. Ozawa T, Faddegon BA, Hu LJ, Bollen AW,
Lamborn KR, Deen DF. Response of
intracerebral human glioblastoma xeno-
grafts to multifraction radiation expo-
sures. Int J Radiat Oncol Biol Phys 2006;
66: 263–70.
30. Shi SR, Key ME, Kalra KL. Antigen retrieval
in formalin-ﬁxed, parafﬁn-embedded tissues:
an enhancement method for immunohisto-
chemical staining based on microwave oven
heating of tissue sections. J Histochem
Cytochem 1991; 39: 741–8.
31. Izumiyama H, Abe T, Tanioka D, Fukuda A,
Kunii N. Clinicopathological examination of
glioma by proton magnetic resonance spec-
troscopy background. Brain Tumor Pathol
2004; 21: 39–46.
32. Howe FA, Barton SJ, Cudlip SA, Stubbs M,
Saunders DE, Murphy M, et al. Metabolic
proﬁles of human brain tumors using quanti-
tative in vivo 1H magnetic resonance spec-
troscopy. Magn Reson Med 2003; 49: 223–32.
33. Sankar T, Caramanos Z, Assina R, Villemure
JG, Leblanc R, Langleben A, et al. Prospective
serial proton MR spectroscopic assessment of
response to tamoxifen for recurrent malig-
nant glioma. J Neurooncol 2008; 90: 63–76.
doi: 10.1007/s11060-008-9632-3
34. Bulik M, Jancalek R, Vanicek J, Skoch A,
Mechl M. Potential of MR spectroscopy for
assessment of glioma grading. Clin Neurol
Neurosurg 2013; 115: 146–53. doi: 10.1016/j.
clineuro.2012.11.002
35. Kaminogo M, Ishimaru H, Morikawa M,
Ochi M, Ushijima R, Tani M, et al. Di-
agnostic potential of short echo time MR
spectroscopy of gliomas with single-voxel and
point-resolved spatially localised proton
spectroscopy of brain. Neuroradiology 2001;
43: 353–63.
36. Zoula S, He´rigault G, Ziegler A, Farion R,
De´corps M, Re´my C. Correlation between
the occurrence of 1H-MRS lipid signal,
necrosis and lipid droplets during C6 rat
glioma development. NMR Biomed 2003; 16:
199–212.
37. Sedlacik J, Winchell A, Kocak M, Loefﬂer RB,
Broniscer A, Hillenbrand CM. MR imaging
assessment of tumor perfusion and 3D
segmented volume at baseline, during treat-
ment, and at tumor progression in children
with newly diagnosed diffuse intrinsic pon-
tine glioma. AJNR Am J Neuroradiol 2013; 34:
1450–5. doi: 10.3174/ajnr.A3421
BJR T Yu et al
10 of 10 birpublications.org/bjr Br J Radiol;88:20140418
